Aerospace Materials Formatting Specialist Web Industries Acquires France-based Omega Systèmes Atlantique and Aquitaine
29.1.2019 01:49:00 EET | Business Wire | Press release
Web Industries, a precision formatter of advanced materials including high performance composites used in the aerospace, defense and industrial markets, announced today that Web Industries International Holdings has acquired 100% of the shares of France-based Omega Systèmes Atlantique and Omega Systèmes Aquitaine. These companies specialize in the formatting of advanced materials for aerospace, defense and industrial applications at production sites in Nantes and Bordeaux.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190128005758/en/
Web Industries Chief Executive Officer Mark Pihl. (Photo: Business Wire)
Synergy
Omega’s formatting technologies, including precision slitting, waterjet cutting, and 5 axis machining, along with ply cutting and kitting, complement Web’s industry leading formatting services. The Omega acquisition is part of Web’s global strategy to provide services and engineering to support aerospace customers’ demand for formatting and materials management services.
“The acquisition of Omega Systèmes is a textbook strategic fit, bringing together the premier U.S. and EU formatters of advanced materials for aerospace,” said Web Industries’ Chief Executive Officer Mark Pihl. “Customers in Europe will soon have access to Web Industries’ technology, systems and scale to support large commercial programs and Web will have local production facilities to meet the demand of Europe’s largest aerospace manufacturers and suppliers. At the same time, many of Omega’s unique capabilities will benefit customers in the North American market.”
Pihl adds, “Omega Systèmes is a strong partner for Web Industries in terms of cultural fit, complementary product and market segment offerings, focus on R&D and geographical reach. We have much in common with Omega Systèmes and are convinced that we can strengthen each other. We are looking forward to growing Omega Systèmes together with Web Industries.”
Jean-Louis Bretin, founder and CEO of Omega, underscores the benefits that the acquisition brings to the business he founded, as well as to Web Industries. “The aerospace industry is entering a new growth phase, which requires large investments for continued sustainable growth,” he says. “With Web Industries, we have found the right partner to expand and scale Omega’s leading role in advanced composites.”
Jean-Louis Bretin will continue to lead Omega and report to Kevin Young, Web Industries’ Vice President of Corporate Development.
According to Young, retaining Bretin is critical to Web’s success in Europe. “Jean-Louis Bretin has shown repeatedly that he understands the market and knows when to adjust his strategy,” he says. “His leadership capabilities, vision, strong customer relationships and knowledge of the aerospace industry will help drive Web’s growth across the continent.”
Transfer of ownership of both companies is effective January 25, 2019.
About Web Industries
A 100% employee-owned company, Web Industries, Inc., is one of the largest and most diverse providers of precision converting and outsource manufacturing. We help customers in the Aerospace, Medical, Personal & Home Care, and Industrial markets bridge their capability gaps and accelerate their go-to-market success by leveraging close, trust-based relationships to develop ingenious solutions precisely tailored to their needs. From project inception through commercialization, Web offers creative problem-solving backed by deep technical and operational expertise. www.webindustries.com
About Omega Systèmes
For over 30 years, OMEGA Systèmes has specialized in the cutting of flexible and semi-rigid materials; first for the textile industry, then notably for the automobile and aeronautic industries. Family-run and independent, the company is a recognized partner in its line of business; their expertise and “advisory” approach are particularly appreciated by their customers. Today OMEGA Systèmes is a partner recognized by major contractors, leading equipment manufacturers, numerous small- and medium-sized companies and administrations as regards to all upstream production phases. http://www.omega-systemes.com/
For Further Information
http://www.omega-systemes.com/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190128005758/en/
Contact information
Web Industries:
+1 508.573.7979
sales@webindustries.com
www.webindustries.com
Omega Systèmes
+33 (0)2.28.25.02.00
accueil@omega-systemes.fr
www.omega-systemes.com/
Media Relations:
Bob Giuliano
+1 610.328.1051
bob.giuliano@prplace.biz
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom